Slide 1: Q4 CellaVision Interim Report Year-end Bulletin 2024
Q4 CellaVision Interim Report Year-end Bulletin 2024 Mixed Regional Performance Sales Peak in APAC Organic sales growth: Q4, 2024: -7% (29) EBITDA margin: Q4, 2024: 33% (36) October 1 – December 31, 2024 Net sales decreased by 7% (+32) to SEK 187 m (201). Sales decreased organically by 7% (+29), cur
Slide 2: CEO's Comment
CEO’s Comment The fourth quarter showcased both the In EMEA, sales reached SEK 74 m (77) – We are also exploring opportunities to extend opportunities and challenges of operating in a decline by 4 percent compared to the FPM into cytology and pathology through dynamic, evolving markets. We maintaine
Slide 3: Sales, Earning and Investments
Sales, Earning and Investments Net Sales and Currency Effects The improved gross margin for the quarter is explained by EBITDA and EBITDA Margin Net sales for the Group’s fourth quarter decreased by 7 percent to favorable mix effects in sales. The slightly lower gross margin EBITDA decreased by 16 p
Slide 4: Investments, Cash Flow, Parent Company
Investments CellaVision continuously capitalizes expenses for product development. Capitalized development expenses increased to SEK 20 m (15) during the quarter due to a higher capitalization rate as certain projects mature. The quarter’s total research and development expenses, before capitalizati
Slide 5: Development in the Geographical Markets
Development in the Geographical Markets Americas: SEK 60 m (87) EMEA: SEK 74 m (77) APAC: SEK 52 m (36) In APAC, sales rose by 44 percent to SEK 52 m (36). This Sales in the Americas decreased by 31 percent to SEK 60 m (87), Sales in EMEA declined by 4 percent to SEK 74 m (77). This growth was prima
Slide 6: Research and Development
Research and Development CellaVision’s ambition is to improve Preliminary evaluations of Fourier healthcare through continuous innovation. Ptychographic Microscopy (FPM) across The company devotes considerable several areas indicate significant progress. resources to research and development to The
Slide 7: Annual General Meeting
Annual General Meeting Annual General Meeting 2025 The Board of Directors proposes to the Annual General Meeting 2025 that a dividend of SEK 2.50 per share be paid for 2024, which is line with the company’s dividend policy. The CellaVision Annual General Meeting in 2025 will be held in Lund at 15:00
Slide 8: Income Statement in Summary, Group
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Group Amounts in ' 000 SEK Note Oct-Dec 2024 Oct-Dec 2023 Jan-Dec 2024 Jan-Dec 2023 Net sales 4 186,688 200,632 723,217 677,292 Cost of goods sold -57,517 -64,710 -236,143 -214,251 Gross profit 129,171 135,922 487,074 46
Slide 9: Per Share Data and Quarterly Earnings Trend
Per Share Data Per share data Oct-Dec 2024 Oct-Dec 2023 Jan-Dec 2024 Jan-Dec 2023 Earnings per share, before and after dilution, SEK */ 1.72 2.11 5.90 5.46 Equity per share, SEK 34.20 30.04 34.20 30.04 Number of shares outstanding 23,851,547 23,851,547 23,851,547 23,851,547 Average number of shares
Slide 10: Balance Sheet in Summary, Group
Balance Sheet in Summary, Group Amounts in ' 000 SEK Note 12/31/2024 12/31/2023 Assets Intangible assets 5 487,646 433,223 Tangible assets 6 119,943 125,502 Financial assets 7 2,653 4,396 Inventory 124,823 126,038 Trade receivables 7 102,824 97,797 Other receivables 7 24,573 20,110 Cash and bank 7 1
Slide 11: Cash Flow Statement in Summary, Group
Cash Flow Statement in Summary, Group Amounts in ' 000 SEK Oct-Dec 2024 Oct-Dec 2023 Jan-Dec 2024 Jan-Dec 2023 Result before taxes 51,489 63,370 176,860 164,222 Adjustment for items not included in cash flow 15,681 10,363 63,144 49,382 Income tax paid -6,877 -11,862 -26,154 -27,561 Cash flow from op
Slide 12: Income Statement in Summary, Parent Company
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Parent Company Amounts in ' 000 SEK Oct-Dec 2024 Oct-Dec 2023 Jan-Dec 2024 Jan-Dec 2023 Net sales 142,494 160,504 555,523 523,473 Cost of goods sold -29,524 -39,913 -133,896 -118,814 Gross profit 112,970 120,591 421,627
Slide 13: Balance Sheet in Summary, Parent Company
Balance Sheet in Summary, Parent Company Amounts in ' 000 SEK 12/31/2024 12/31/2023 Assets Intangible assets 26,944 29,935 Tangible assets 7,074 5,770 Deferred tax assets 755 496 Long term receivables from group companies 32,162 35,507 Financial assets 261,220 263,133 Inventory 86,655 86,815 Trade r
Slide 14: Notes
Notes NOTE 1. ACCOUNTING POLICIES NOTE 3. RISKS AND UNCERTAINTIES The Group applies IFRS Accounting Standards, as adopted by the EU. This interim report has CellaVision is exposed to several risks, which may impact the Group’s development to a greater been prepared in accordance with IAS 34 Interim
Slide 15: Notes, Cont'd
Notes, Cont’d NOTE 5. INTANGIBLE ASSETS NOTE 7. FINANCIAL ASSETS AND LIABILITIES Amounts in ' 000 SEK 12/31/2024 12/31/2023 The disclosed value of financial assets, trade receivables, other receivables, cash and bank, Capitalised expenditure for development 267,984 209,864 trade payables, and other
Slide 16: Reconciliation Tables KPIs, Non-IFRS Measures
Reconciliation Tables KPIs, Non-IFRS Measures The company presents certain financial measures in the Definitions of measures which are not defined according to Gross margin. Gross profit as a percentage of net sales. interim report which are not defined according to IFRS. The IFRS and which are not
Slide 17: Questions Concerning the Report
Questions Concerning the Report Publication This information constitutes information that CellaVision AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 7:20 a.m. CET on February 6, 2025. CellaVision is listed on the Nasda
Slide 18: This is CellaVision
This is CellaVision About Us Our Strategic Ambition: The power of focus Mission CellaVision is an innovative, global medical technology company Our strategic ambition is to digitalize and improve microscopy To advance laboratory workflow and that develops and sells its own leading solutions for rout